IceCure Medical's ProSense® Cryoablation Granted FDA Marketing Authorization for Treatment of Low-Risk Breast Cancer in Women Aged 70 and Above: Significant Development in Giving Women with Breast Cancer Minimally Invasive Care

Core Insights - The FDA has granted marketing authorization for ProSense®, a minimally invasive cryoablation treatment for early-stage low-risk breast cancer, marking a significant innovation in breast cancer treatment [1] - ProSense® offers a non-surgical option that destroys tumors by freezing, providing efficacy and safety comparable to standard lumpectomy, along with excellent cosmetic results and high patient satisfaction [1] - The treatment is specifically indicated for women aged 70 and over, with an estimated annual patient population of 46,000 in the U.S. [1] Company Overview - IceCure Medical Ltd. is the developer of the ProSense® technology, which represents the first new innovation in local treatment for early-stage breast cancer in decades [1] - The company is publicly traded on Nasdaq under the ticker ICCM [1] - A conference call is scheduled for October 6, 2025, to discuss the implications of this FDA authorization [1]